Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Bind Therapeutics
 More »

  • Alchemia, AstraZeneca Partner on $240M Multi-Target Drug Discovery...
    Yesterday, the pharma firm announced collaborations with Horizon Discovery and BIND Therapeutics . The drug discovery firm and the pharma giant have set a multi-target drug ...
    4-23-2013
  • Horizon, AstraZeneca Seek Kinase-Targeting Cancer Drugs
    In a separate deal said to be worth over $200 million, AZ will also be working with BIND Therapeutics to develop and commercialize a targeted and programmable cancer nanomedicine. ...
    4-22-2013
  • AstraZeneca, BIND Enter $200M+ Cancer Nanomedicine Agreement
    BIND Therapeutics and AstraZeneca today announced they are working together to develop and commercialize a targeted and programmable cancer nanomedicine. The companies are ...
    4-22-2013
  • Advances in RNAi Tools and Technologies
    modifications) that bind to a miRNA of interest and reduce its intracellular levels. ... of siRNAs in RNAi-mediated therapeutics, shRNAs are also important tools for ...
    4-15-2013
  • Pfizer, BIND Launch $210M+ Targeted Nanomedicine Collaboration
    BIND Therapeutics today said it entered into a collaboration with Pfizer to develop and commercialize a new class of highly selective targeted and programmable therapeutics called ...
    4-2-2013
  • Genome Editing for R&D and Therapeutics
    ... Gregory, "All technologies share the common goal of targeting the genome for therapeutics. ... But unlike ZFNs that bind to groups of three base pairs, TALENs binds to individual ...
    3-1-2013
  • Addressing Unmet Medical Needs with Complex Carbohydrate Chemistry
    Manchester, NH-based Boston Therapeutics developed this treatment under the name PAZ320 ... been shown to bind to TNF-α and thereby block immune system activation and inflammation. ...
    2-28-2013
  • Exploiting miRNA's Potential for Diagnostics and Drugs
    ... this problem because some major inhibitors cannot bind to this truncated polymerase. Dr. ... Viral-Mediated miRNA Therapeutics Cellular delivery of miRNAs via cytoplasmic-based ...
    2-15-2013
  • Amgen, BIND in Up-to-$180.5M Cancer Partnership
    for targeted and programmable nanomedicines to create therapeutics called Accurins(tm). Amgen agreed to pay BIND up to $46.5 million in up-front and development milestone ...
    1-8-2013
  • Mayans Give Big Data a Big Break
    It's a heady mix of small- and large-molecule therapeutics, technology, disease ... a reality and bind the parties together in precompetitive and discreet relationships. ...
    1-4-2013
  • Shire, Arrowhead Launch PDC Collaboration
    In Shire's latest collaboration, Arrowhead will identify peptides that selectively bind ... The platform is designed to enable creation of guided therapeutics that specifically ...
    12-18-2012
  • Top 20 Venture Capital Firms
    portfolio companies: Achaogen, Acylin Therapeutics, Agios Pharmaceuticals, Allozyne, Alnylam Holdings, Array BioPharma, BIND Biosciences, bluebird bio, Caliper Life ...
    12-17-2012
  • Antisense Making Sense to Isis Partners
    The Isis discovery platform develops specific therapies that bind to messenger RNA and ... of novel generation antisense therapeutics against five cancer targets. Antisense ...
    12-11-2012
  • Epigenetics Reshapes the Therapeutic Arena
    ... individual noncoding RNA molecules that bind PRC2 to repress the expression of individual genes. "Oligonucleotide therapeutics are particularly well suited for this, ...
    12-1-2012
  • Cancer Research Firms Eye ADCs to Extend Portfolios
    ... Because these ADCs are designed to treat gene-mediated diseases, they bind to genomic DNA ... II trials in 2010 for ovarian cancer, and agreements with Genentech and ADC Therapeutics. ...
    12-1-2012
  • More »

    Journal Articles

  • Effects of Plasminogen Activator Inhibitor-1-Specific RNA Aptamers...
    Stephanie Brandal, Charlene M. Blake, Bruce A. Sullenger, Yolanda M. Fortenberry
    Nucleic Acid Therapeutics
    Nucleic Acid Therapeutics The serine protease inhibitor (serpin) plasminogen activator ... Integrins present on the cell surface bind to vitronectin and anchor the cell to the ...
  • Dissection of the Functional Structure of Aptamer17, Which Specificall...
    Jiao-Jiao Liu, Cheng-Long Wang, Qing Xi, Juan Xu, Bin Deng, Hong-Mei Ding, Bingfeng Chu, Dong-Hua Su
    Nucleic Acid Therapeutics
    Nucleic Acid Therapeutics A specific single-stranded DNA (ssDNA) aptamer (aptamer17) that ... aptamers with this basic structure could bind specifically to differentiated PC12 cells ...
  • Anti-caveolin-1 Antibodies As Anti-Prostate Cancer Therapeutics
    Shu-Ru Kuo, Salahaldin A. Tahir, Sanghee Park, Timothy C. Thompson, Scott Coffield, Arthur E. Frankel, Jen-Sing Liu
    Hybridoma
    Anti-caveolin-1 Antibodies As Anti-Prostate Cancer Therapeutics Hybridoma Caveolae are ... and 80; CSD with 2 antibodies potentially bind the scaffolding domain (amino acid ...
  • HER2-Mediated Internalization of a Targeted Prodrug Cytotoxic...
    Veronique Guillemard, Hinyu N. Nedev, Alan Berezov, Ramachandran Murali, H. Uri Saragovi
    DNA and Cell Biology
    There are no natural ligands, but monoclonal antibodies and peptides that bind HER2 act as ... and the chemical conjugation strategy may yield improved and HER2 selective therapeutics.

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll